InMed Pharmaceuticals Inc. (INM) Cash Flow Statement
Where INM’s cash came from and went, FY2026
June 30, 2026 · U.S. dollars- Cash from operations
- −$8.64B
- Capital expenditures
- $3 0.0% of revenue
- Free cash flow
- −$8.64B −272.1% margin
- Returned to shareholders
- $431.7M
- Change in cash
- −$8.55B cash at year-end $2.19B
Drawn to scale: where the cash came from and how it was used. Hover for values.
INM operating cash flow, capex and free cash flow
INM cash flow trends, FY2025–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$7.8MFY2025 | −$8.64BFY2026 | — | |
| Capital expenditures | $0FY2025 | $3FY2026 | — | |
| Free cash flow | −$7.8MFY2025 | −$8.64BFY2026 | — | |
| Free cash flow margin | −157.1%FY2025 | −272.1%FY2026 | −115.0 pts | |
| Stock-based compensation | $119,307FY2025 | $106.9MFY2026 | +89,472.3%/yr | |
| Capex / revenue | 0.0%FY2025 | 0.0%FY2026 | 0.0 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
INM cash flow by activity
INM net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
INM cash flow statement
| FY2026 | FY2025 | |
|---|---|---|
| Operating activities | ||
| Net income | −$12.56B | −$8.2M |
| Depreciation & amortization | $708,356 | $534,725 |
| Stock-based compensation | $106.9M | $119,307 |
| Change in working capital | −$76,136 | −$337,167 |
| Other non-cash items | $3.81B | $78,317 |
| Cash from operating activities | −$8.64B | −$7.8M |
| Investing activities | ||
| Capital expenditures | −$3 | $0 |
| Investments (net) | $0 | $0 |
| Financing activities | ||
| Dividends paid | −$431.7M | — |
| Shares issued | $231,675 | $8.1M |
| Other financing | $525.9M | $4.1M |
| Cash from financing activities | $94.5M | $12.3M |
| Summary | ||
| Net change in cash | −$8.55B | $4.5M |
| Cash at end of period | $2.19B | $11.1M |
| Free cash flow | −$8.64B | −$7.8M |
| Free cash flow margin | −272.1% | −157.1% |
| Capex / revenue | 0.0% | 0.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | −$14.58B | −$2.8M | −$3.75B | −$2.4M | −$1.8M | −$2.1M | −$2.6M |
| Depreciation & amortization | $260,199 | $133,458 | $158,019 | $156,680 | $131,083 | $129,583 | $129,079 |
| Stock-based compensation | $132.0M | $38,771 | $45.4M | $20,205 | $26,730 | $40,454 | $23,159 |
| Change in working capital | −$962,204 | −$183,784 | −$821,011 | −$82,233 | −$180,883 | $265,418 | −$94,065 |
| Other non-cash items | $14.45B | $1.0M | $3.71B | $71,715 | $32,875 | $25,978 | $14,713 |
| Cash from operating activities | −$2.9M | −$1.8M | −$3.2M | −$2.2M | −$1.8M | −$1.7M | −$2.5M |
| Investing activities | |||||||
| Capital expenditures | −$5 | −$4 | −$5 | $0 | $0 | $0 | $0 |
| Investments (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing activities | |||||||
| Dividends paid | −$431.7M | — | — | — | — | — | — |
| Shares issued | $0 | $231,675 | $0 | $0 | $3.8M | $2.9M | $396,153 |
| Other financing | $431.7M | −$191 | $1,158 | −$191,326 | $4.4M | −$15,103 | −$57,632 |
| Cash from financing activities | −$827 | $231,484 | $1,158 | −$191,326 | $8.2M | $2.9M | $338,521 |
| Summary | |||||||
| Net change in cash | −$3.0M | −$1.8M | −$3.3M | −$2.4M | $6.4M | $1.3M | −$2.2M |
| Cash at end of period | $2.2M | $5.2M | $9.5M | $13.0M | $11.1M | $4.7M | $3.4M |
| Free cash flow | −$2.9M | −$1.8M | −$3.2M | −$2.2M | −$1.8M | −$1.7M | −$2.5M |
| Free cash flow margin | −0.1% | −0.3% | −286.7% | −200.2% | −100.1% | −131.5% | −225.1% |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
INM cash generation
In fiscal 2026 (ended June 30, 2026), InMed Pharmaceuticals generated -$8.6 billion of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$8.6 billion, −272.1% of revenue. It returned $431.7 million to shareholders through dividends ($431.7 million) and net share buybacks ($0). Cash and equivalents fell by $8.5 billion over the year.
Related: INM income statement, INM balance sheet. See the INM stock overview for the latest quote and news.
INM cash flow FAQ
What is InMed Pharmaceuticals's free cash flow?
InMed Pharmaceuticals's free cash flow was -$8.6 billion in fiscal 2026: -$8.6 billion of operating cash flow minus $0.0 million of capital expenditures It was -$7.8 million a year earlier..
How much cash does InMed Pharmaceuticals generate from operations?
InMed Pharmaceuticals generated -$8.6 billion of cash from operating activities in fiscal 2026.
How much does InMed Pharmaceuticals spend on capital expenditures?
InMed Pharmaceuticals spent $0.0 million on capital expenditures in fiscal 2026, 0.0% of revenue.
How much does InMed Pharmaceuticals pay in dividends?
InMed Pharmaceuticals paid $431.7 million in dividends in fiscal 2026.